Innovation Pathway Advances May Be Expanded Throughout Agency
CINCINNATI — Regulatory advances made during the Innovation Pathway 2.0 project to develop new treatments for end-stage renal disease may quickly be rolled throughout CDRH, center Director Jeffrey Shuren said Wednesday at the FDA/Xavier University MedCon Conference here. Innovation Pathway is designed to help speed breakthrough technologies to market through greater work with devicemakers and the use of outside experts, including entrepreneurs. Phase two, focusing on the development of four treatments for end-stage renal disease, was announced last month. Devices & Diagnostics Letter
"There were "gems" of current thinking that came up with much greater frequency than at other conferences."
"Robust presentation content. Great networking opportunity."
"Really appreciated that this was a hands on conference with so many FDA speakers and other regulators."
"Very informative. Great mix of industry personnel and FDA representation. Great opportunity to ask questions, share information and network."
"Very good network opportunity with other experts and lead resources!"
"The list of presenters/subject experts were carefully selected to include individuals that were knowledgeable with current regulatory information, articulate and personable."
